Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tetatox is a monovalent tetanus vaccine developed and manufactured by the Bulgarian state-owned biomedical company BulBio (BB-NCIPD EAD). The vaccine consists of purified tetanus toxoid, which is typically adsorbed onto an aluminum adjuvant (such as aluminum hydroxide or aluminum phosphate) to enhance the immune response. Tetatox works by inducing the production of specific neutralizing antibodies against the tetanus toxin produced by the bacterium *Clostridium tetani*. It is indicated for the active immunization against tetanus in children and adults, and is also used for post-exposure prophylaxis in wound management to prevent the development of clinical tetanus.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tetatox.